Navigation Links
The "DNDi Project of the Year": The Development of Fexinidazole to Treat "Sleeping Sickness"
Date:6/27/2008

NERVIANO, Italy, June 27 /PRNewswire/ --

- Accelera Recognised as Key Partner in the Development of a New Therapy

The development of fexinidazole for the treatment of African trypanosomiasis, commonly known as "sleeping sickness", by DNDi (Drugs for Neglected Diseases initiative), along with Accelera, a business unit of Nerviano Medical Sciences (NMS), is to be honoured as one of DNDi's Success Stories of the Year. The award will be conferred today in New York, at the prestigious headquarters of the New York Academy of Sciences, during the first annual Stakeholders' Meeting of DNDi. Accelera is recognised as DNDi's key partner in the non-clinical development of fexinidazole.

"We are proud to receive this recognition," comments Dr. Marco Brughera - Vice President of Accelera - "and happy to be able to contribute to improving the health of populations living in the poorest countries. We were delighted to be selected from among several international Contract Research Organisations (CROs) to be DNDi's partner of choice for characterizing the preclinical profile of fexinidazole"

"The preclinical work to support the profiling of fexinidazole started at Accelera more than one year ago," Dr Brughera points out "and included a series of in vitro and preliminary activities followed by a full package of tolerability and safety studies as requested by Regulatory Authorities. The results obtained have allowed DNDi to proceed to the next stage of fexinidazole's development, with a quick registration being a primary goal."

Accelera carries out preclinical development activities for molecules targeting various different therapeutic classes, including collaborations aimed at defining therapeutic solutions for other "neglected diseases," such as malaria, visceral leishmaniasis, African trypanosomiasis, and Chagas' disease.

"Our pride in this recognition is twofold: on the one hand there is the satisfaction of being an active collaborator within such international projects, and on the other the knowledge that we have been able to make our contribution to a humanitarian initiative like that of DNDi," continues Giampiero Duglio, Managing Director of NMS.

About Accelera (http://www.accelera.info)

Accelera, BU of Nerviano Medical Sciences, is a premium tier Contract Research Organization (CRO), working and collaborating with pharmaceutical and biotechnology companies around the world. Committed to offering the highest levels of service throughout drug discovery and development, our expertise can make a difference, right from the start.

About Nerviano Medical Sciences - NMS (http://www.nervianoms.com)

NMS is a research based company dedicated to the discovery and development of breakthrough new chemical entities (NCEs) for the treatment of cancer. NMS was incorporated in May 2004 as a spin-off from Pfizer and is wholly owned by the Rome-based Congregazione dei Figli dell'Immacolata Concezione (CFIC).

For further information please contact:

Accelera (Nerviano Medical Sciences)

Maria D'Acquino, mob +39-335-1863052

maria.d'acquino@nervianoms.com


'/>"/>
SOURCE Nerviano Medical Sciences (NMS): Accelera
Copyright©2008 PR Newswire.
All rights reserved

Related medicine news :

1. QI projects may -- or may not -- improve patient safety and outcomes
2. MU researchers to collaborate on $20 million project
3. Fry Construction Selected for High-Profile Medical Imaging Project
4. Jacobs Receives Contract for New Hospital Project in Belgium
5. IVCC launches groundbreaking insecticide projects with Bayer and Syngenta
6. Global Health Project targets reducing AIDS among Indias adolescents
7. Uncontrolled Blood Pressure Highest Among Hispanics, Prompting New Hypertension Project in San Antonio
8. New Business Development of Multi-Hospital Project!
9. ARIZONA METH PROJECT Unveils Arizonas Anti-Meth Youth Pledge and Kicks Off Phase Two of Public Awareness Campaign
10. Meth Project Advertisements Selected for National Prevention Campaign
11. Pillow, PAs Great American Sleep Better(TM)Project Reports Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/2/2016)... ... ... Lori G. Cohen and Sara K. Thompson , shareholders in global law ... 21st Drug & Medical Device Litigation Conference , taking place in New York Dec. ... chairs the firm’s Pharmaceutical, Medical Device & Health Care Litigation Practice and the Trial ...
(Date:12/2/2016)... ... , ... Advanced Inc., a leading provider of travel therapy and travel nursing ... as Advanced Inc.’s Chief Financial Officer, effective December 1, 2016. Jason previously served as ... operational leadership experience to Advanced Inc. He began his career in finance at Ernst ...
(Date:12/2/2016)... ... ... With the number of pain management programs available for people suffering with constant ... works for them. When an inventor from Suisun City, Calif., was unsuccessful in finding ... it with others. , He developed a prototype for PRO GO MASSAGE to relieve ...
(Date:12/2/2016)... ... December 02, 2016 , ... CloudLIMS.com, a ... SaaS LIMS, CloudLIMS Lite. CloudLIMS Lite helps biobanks, clinical, research and testing laboratories ... and disposal. The new version is a faster and a more efficient product, ...
(Date:12/2/2016)... ... 02, 2016 , ... Yisrayl Hawkins, at The House of Yahweh in Abilene, ... into Bible Prophecy. Yisrayl says this generation, known as the Last Generation, started in ... the details line up exactly with Bible Prophecy – a protected way for those ...
Breaking Medicine News(10 mins):
(Date:12/2/2016)... , December 2, 2016 On ... Committee honored excellence in research, development and innovation in ... gala dinner was held in the presence of Sergey ... Russian Federation , Natalia Sanina, First ... Mikhail Murashko , Head of Roszdravnadzor, National Service of ...
(Date:12/2/2016)... CVS Health Corporation (NYSE: CVS ... City on Thursday, December 15, 2016, beginning at 8:00 a.m. (ET). Senior ... an in-depth review of the company,s strategies to drive ... also discuss 2017 earnings guidance during the event. ... will be broadcast simultaneously on the Investor Relations portion ...
(Date:12/2/2016)... -- On Thursday, the NASDAQ Composite and the ... Dow Jones Industrial Average managed to stay in green. Losses ... prompted Stock-callers this morning to look at the performances of ... ), Smith & Nephew PLC (NYSE: SNN ), ... Therapeutics Inc. (NASDAQ: KOOL ). You can access ...
Breaking Medicine Technology: